MERCK & CO., INC. (NYSE:MRK)
105.06 USD 
+1.60 (+1.55%)
Delayed Price / Updated:
4:00 PM EST, Dec 04, 2023 / Add to My Watchlist
Company Information
Financial Snapshot
| Annual | 12/2022FY | 12/2023FY |
|---|---|---|
| Total Revenue | $48.91 B | $58.47 B |
| Net Income | $13.05 B | $14.52 B |
| Quarterly | 3/31/2023 | 6/30/2023 |
| Total Assets | $107.8 B | $104.47 B |
| Total Liabilities | $65.73 B | $65.43 B |
| Operating Margin | 26.98% | -32.51% |
Address and Details
| Merck & Co., Inc.
2000 Galloping Hill Road |
|
| Industry | Pharmaceuticals: Major |
|---|---|
| Sector | Health Technology |
| Employees | 69,000 |
Business Summary
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Company Officers
| Mr. Robert M. Davis | Mr. Robert M. Davis | Ms. Caroline A. Litchfield | ||||||||||||||||||||||||||
| Chairman, President & Chief Executive Officer | Chairman, President & Chief Executive Officer | Chief Financial Officer & Executive Vice President | ||||||||||||||||||||||||||
| Mr. Dave Williams | Dr. Risa J. Lavizzo-Mourey | Dr. Risa J. Lavizzo-Mourey | Dr. Stephen L. Mayo | Dr. Stephen L. Mayo | Dr. Milenko Cicmil | Mr. Douglas M. Baker | Mr. Douglas M. Baker | Mr. Thomas Henry Glocer | Mr. Thomas Henry Glocer | Ms. Patricia Fiorello Russo | Ms. Patricia Fiorello Russo | Mr. Peter C. Wendell | Mr. Peter C. Wendell | Ms. Mary Ellen Coe | Ms. Kathy J. Warden | Dr. Christine E. Seidman | Dr. Christine E. Seidman | Ms. Kathy J. Warden | Mr. Robert M. Davis | Ms. Pamela J. Craig | Ms. Pamela J. Craig | Dr. Paul B. Rothman | Dr. Paul B. Rothman | Mr. Inge G. Thulin | Mr. Inge G. Thulin | Ms. Mary Ellen Coe | Ms. Kelly E. W. Grez | |
| Chief Information & Digital Officer | Independent Director | Independent Director | Independent Director | Independent Director | Director | Independent Director | Independent Director | Lead Independent Director | Lead Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Chairman, President & Chief Executive Officer | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Secretary |
Revenue, Returns and Ratios
Total Revenue - TTM
;Total|Revenue(Prev%20Qtr)&BAR_VALUE_SUFFIX=B&YAXIS_LABEL_SUFFIX=B&BAR_WIDTH=90&BAR_VALUE_PREFIX=$&YAXIS_LABEL_PREFIX=$)
Ratios
;P/E|Ratio%20(FY);Debt/Equity|Ratio%20(MRQ)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Revenue Summary - TTM
Return on Equity vs. Return on Assets
;Return%20on|Assests%20(MRQ)&BAR_VALUE_SUFFIX=%25&YAXIS_LABEL_SUFFIX=%25&BAR_WIDTH=90)
Per Share
;Cash%20Flow%20Per|Share%20(FY)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Peer Comparison
| Company Name | Price | EPS (FY) | Annual Dividend | Book Value (FY) | Cash Flow (FY) |
|---|---|---|---|---|---|
| Merck & Co., Inc. | $105.06 | 1.82 | 2.80 | 16.27 | 7.85 |
Latest News
More Headlines
Latest News
Market Data
Stock Watchlist
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.